TY  - EJOU
AU  - WANG, JIAHUI 
AU  - GE, HONGCHENG 
AU  - YU, ZHENGAN 
AU  - WU, LINGZHI 

TI  - Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy
T2  - Oncology Research

PY  - 2025
VL  - 33
IS  - 5
SN  - 1555-3906

AB  - 
Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes immune escape through changes in the expression of immune checkpoints. The aim of this review is to understand the effects of ncRNAs on the occurrence and development of lung cancer, focusing on the role of ncRNAs in regulating drug resistance of lung cancer.
KW  - Non-coding RNAs (ncRNAs); Lung cancer; Drug resistance; Immunotherapy; Chemotherapy; Immune checkpoints; Immune escape

DO  - 10.32604/or.2024.058256